Lista de obras -

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

artículo científico publicado en 2005

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma ⬇️

artículo científico publicado el 18 de agosto de 2011

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

artículo científico publicado en 2014

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

artículo científico publicado en 2010

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

artículo científico publicado en 2002

Antimyeloma activity of heat shock protein-90 inhibition.

artículo científico publicado en 2005

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

artículo científico publicado en 2009

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

artículo científico publicado en 2003

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

artículo científico publicado en 2008

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

artículo científico publicado en 2002

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

artículo científico publicado en 2011

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

artículo científico publicado en 2006

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

artículo científico publicado en 2002

Bortezomib in the front-line treatment of multiple myeloma

artículo científico publicado en 2008

Bortezomib in the management of multiple myeloma ⬇️

artículo científico publicado el 8 de septiembre de 2009

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

artículo científico publicado en 2009

Bortezomib: proteasome inhibition as an effective anticancer therapy

artículo científico publicado en 2006

Can thalidomide improve outcome in patients with multiple myeloma?

scientific article published on 01 November 2006

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

artículo científico publicado en 2009

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

artículo científico publicado en 2004

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

artículo científico publicado en 2012

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

artículo científico publicado en 2010

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

artículo científico publicado en 2002

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

artículo científico publicado en 2015

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

artículo científico publicado en 2007

Emerging drugs in multiple myeloma

artículo científico publicado en 2007

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

artículo científico publicado en 2009

Emerging trends in the clinical use of bortezomib in multiple myeloma

artículo científico publicado en 2005

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study ⬇️

artículo científico publicado el 13 de diciembre de 2012

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

artículo científico publicado en 2005

From the bench to the bedside: emerging new treatments in multiple myeloma

artículo científico publicado en 2007

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

artículo científico publicado en 2009

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

artículo científico publicado en 2011

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

artículo científico publicado en 2006

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents

artículo científico publicado en 2012

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

artículo científico publicado en 2002

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

artículo científico publicado en 2003

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

artículo científico publicado en 2009

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2007

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers ⬇️

artículo científico publicado el 10 de enero de 2011

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

artículo científico publicado en 2003

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

artículo científico publicado en 2009

Lenalidomide in multiple myeloma

artículo científico publicado en 2006

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

artículo científico publicado el 15 de junio de 2010

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

artículo científico publicado en 2011

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2010

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias

artículo científico publicado el 1 de junio de 2011

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

scientific article published on 01 October 2006

Management of Relapsed and Relapsed/Refractory Multiple Myeloma ⬇️

artículo científico publicado el 1 de octubre de 2011

Management of myeloma-associated renal dysfunction in the era of novel therapies

artículo científico publicado en 2012

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

artículo científico publicado el 7 de julio de 2011

Maximizing the clinical benefit of novel therapies in multiple myeloma

scientific article published on April 2009

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

artículo científico publicado en 2004

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

artículo científico publicado en 2010

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells

artículo científico publicado en 2012

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation

artículo científico publicado en 2011

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

artículo científico publicado en 2012

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

artículo científico publicado en 2011

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

artículo científico publicado en 2005

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

artículo científico publicado en 2002

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

artículo científico publicado en 2003

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

artículo científico publicado en 2002

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

artículo científico publicado en 2009

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

artículo científico publicado en 2007

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

artículo científico publicado en 2016

NF-kappa B as a therapeutic target in multiple myeloma

artículo científico publicado en 2002

New drugs for myeloma

artículo científico publicado en 2007

New proteasome inhibitors in myeloma

artículo científico

Novel biological therapies for the treatment of multiple myeloma

artículo científico publicado en 2005

Novel biologically based therapies for Waldenstrom's macroglobulinemia

artículo científico publicado en 2003

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

artículo científico publicado en 2007

Novel therapies in myeloma

artículo científico publicado en 2007

Novel therapies in the treatment of multiple myeloma

artículo científico publicado en 2009

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

artículo científico publicado en 2003

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2006

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

artículo científico publicado en 2008

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

artículo científico publicado en 2010

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

artículo científico publicado en 2013

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias

artículo científico publicado en 2009

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy ⬇️

artículo científico publicado el 27 de octubre de 2011

Proteasome inhibition as a new therapeutic principle in hematological malignancies

artículo científico publicado en 2006

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

artículo científico publicado en 2005

Proteasome inhibition in hematologic malignancies

artículo científico publicado en 2004

Proteasome inhibition in the treatment of cancer

artículo científico publicado en 2005

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

artículo científico publicado en 2003

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

artículo científico publicado en 2002

Proteasome inhibitor therapy in multiple myeloma

artículo científico publicado en 2005

Proteasome inhibitors as therapeutics

artículo científico publicado en 2005

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

artículo científico publicado en 2017

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

artículo científico publicado en 2009

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

artículo científico publicado en 2010

Tanespimycin as antitumor therapy.

artículo científico publicado en 2011

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

artículo científico publicado en 2004

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

artículo científico publicado en 2006

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

artículo científico publicado en 2004

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma ⬇️

artículo científico publicado el 1 de febrero de 2011

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* ⬇️

artículo científico publicado el 22 de noviembre de 2011

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

artículo científico publicado en 2003

The emerging role of novel therapies for the treatment of relapsed myeloma

artículo científico publicado en 2007

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

artículo científico publicado en 2013

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib ⬇️

artículo científico publicado el 7 de marzo de 2012

The power of proteasome inhibition in multiple myeloma

scientific article published on 14 November 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

artículo científico publicado en 2002

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

artículo científico publicado en 2007

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

artículo científico publicado en 2006

The treatment of multiple myeloma patients not eligible for asct ⬇️

artículo científico publicado el 3 de mayo de 2010

The treatment of relapsed and refractory multiple myeloma

artículo científico publicado en 2007

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

artículo científico publicado en 2010

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

artículo científico publicado en 2007

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

artículo científico publicado en 2004

Lista de obras de

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma ⬇️

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

Antimyeloma activity of heat shock protein-90 inhibition.

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

Bortezomib in the front-line treatment of multiple myeloma

Bortezomib in the management of multiple myeloma ⬇️

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

Bortezomib: proteasome inhibition as an effective anticancer therapy

Can thalidomide improve outcome in patients with multiple myeloma?

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

Emerging drugs in multiple myeloma

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

Emerging trends in the clinical use of bortezomib in multiple myeloma

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study ⬇️

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

From the bench to the bedside: emerging new treatments in multiple myeloma

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers ⬇️

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

Lenalidomide in multiple myeloma

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

Management of Relapsed and Relapsed/Refractory Multiple Myeloma ⬇️

Management of myeloma-associated renal dysfunction in the era of novel therapies

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

Maximizing the clinical benefit of novel therapies in multiple myeloma

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

NF-kappa B as a therapeutic target in multiple myeloma

New drugs for myeloma

New proteasome inhibitors in myeloma

Novel biological therapies for the treatment of multiple myeloma

Novel biologically based therapies for Waldenstrom's macroglobulinemia

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

Novel therapies in myeloma

Novel therapies in the treatment of multiple myeloma

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.